← Back to Calendar
Live Company Data
NMS
Updated
45m ago
· Data: FMP
Current Price
$1.68
+32.28%
+$0.41 today
Day: $1.66 – $1.74
Market Cap
N/A
Shares out: 640.90M
Float: 510.78M
52-Week Range
Current price is at 66% of 52-week range
Sector
Healthcare
Biotechnology
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Indication
Myelofibrosis (MF) — overall survival analysis
Key Notes
IMpactMF Phase 3 interim overall survival (OS) analysis expected H2 2026 (company guidance). Phase 3 trial comparing imetelstat to best available therapy in transfusion-dependent patients with relapsed/refractory myelofibrosis who are JAK inhibitor-intolerant or progressed on JAK inhibitor. Positive OS data would support regulatory filings in myelofibrosis — a large potential new indication for Rytelo alongside its approved MDS indication. Geron MDS sBLA PDUFA April 15, 2026 will be decided before this readout.
⚠️ Not Investment Advice: This information is provided for educational purposes only.
PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period,
issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on
historical base rates and do not account for drug-specific factors. Always consult a financial advisor
before making investment decisions.
Discussion
Share your analysis, research, or questions about this catalyst. No account required.